metformin has been researched along with sb 203580 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Dey, CS; Kumar, N | 1 |
| Guo, H; Ji, M; Peng, Z; Shi, H; Shi, M; Xie, Y | 1 |
3 other study(ies) available for metformin and sb 203580
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Metformin enhances insulin signalling in insulin-dependent and-independent pathways in insulin resistant muscle cells.
Topics: Animals; Cells, Cultured; Deoxyglucose; Hypoglycemic Agents; Imidazoles; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Metformin; Mice; Mitogen-Activated Protein Kinases; Muscle, Skeletal; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Pyridines; Receptor, Insulin; Signal Transduction; Tyrosine | 2002 |
Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin‑resistant ovarian cancer.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Imidazoles; Metformin; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Pyridines | 2014 |